NR 546 Week 3 Assignment; Antipsychotic
ss ss ss ss ss
Medications Table questions and detailed answers
ss ss ss ss ss ss ss
all question upgraded /newest version[grade a+]
ss ss ss ss ss ss
Antipsychotic Medications
ss
Kristin ssReddy ssNR ss546 ssSeptember
ss2022
Drug ssname Indication ss(Bold ss= ssFDA ssapproved) Half-life Notable ssside sseffects ss(associate ssto sspathway ssor ssNT)
Target sssymptoms: ssstate ssif sspositive ssor ssnegative s(T1/2),
sseffectsPotency ss(if ssnoted. ssreceptor ssoccupancy ssif metabolism
ssnoted) ssNeurotransmitter(s) ssaffected s(CYP ss450
enzyme)
Typical ssantipsychotics ss(conventional)
,Haloperidol Indication: Half s s Life ▪ Neuroleptic-induced ssdeficit sssyndrome ss– ssBlocking
▪ Manifestations ssof sspsychotic ssdisorders ssOral: ssofsdopamine sstwo ssreceptors ssexcessively ssin ssthe
ss(oral,simmediate-release ssinjection) ssApproximat mesocortical ssand ssmesolimbic ssdopamine
▪ Tics ssand ssvocal ssutterances ssin ssTourette’s sssyndrome elsy ss12-38 sspathways, sspecially ssat sshigh ssdoses, ssit sscan
ss(oral,simmediate-release ssinjection) hours sscause ssworsening ssof ssnegative ssand sscognitive
▪ Second-line sstreatment ssof sssevere ssbehavior sssymptoms
ssproblems ssinschildren ssof sscombative, ssexplosive Decanoate: ▪ Akathisia ss- ssAcute ssblockade ssof ssdopamine ss2
sshyperexcitability ss(oral) ssreceptorssin ssthe ssstriatum
ssapproximat
▪ Second-line ssshort-term sstreatment ssof elsy ss3 ssweeks ▪ Drug-induced ssparkinsonism ss- ssAcute ssblockade
ssofsdopamine ss2 ssreceptors ssin ssthe ssstriatum
sshyperactiveschildren ss(oral)
▪ Treatment ssof ssschizophrenic sspatients sswho ▪ Tardive ssdyskinesia, sstardive ssdystonia ss– ssChronic
ssandsacute ssblockade ssof ssdopamine ss2 ssreceptors
ssrequire ssprolonged ssparenteral ssantipsychotic Metabolized
ssin ssthe ssstriatum
sstherapy ss(depotsintramuscular ssdecanoate) sby ssCYP450
▪ Bipolar ssdisorder ▪ Risk ssof sspotentially ssirreversible
ss- ss2D6,
ssinvoluntary sdyskinetic ssmovements ssmay
▪ Behavioral ssdisturbances ssin ssdementias ss3A4,
ssincrease sswith sscumulative ssdose ssand
▪ Delirium ss(with 3A5
sstreatment ssduration
sslorazepam)sTarget sssymptoms:
▪ Positive sssymptoms ssof sspsychosis ▪ Galactorrhea, ssamenorrhea ss– ssBlocking ssof
ssdopamines2 ssreceptors ssin ssthe sspituitary sscan
▪ Violent ssor ssaggressive
sscause sselevations ssin
ssbehaviorsPotency: ssHigh
Neurotransmitter(s) ssaffected: prolactin
▪ Blocks ssdopamine ss2 ssreceptors, ssreducing ▪ Dizziness, sssedation ss– ssBlocking ssof ssalpha ss1
ssadrenergicsreceptors
sspositive ssymptoms ssof sspsychosis ssand sspossibly
sscombative, sexplosive, ssand sshyperactive
▪ Dry ssmouth, ssconstipation, ssurinary ssretention,
ssblurred ssvision, ssdecreased sssweating ss–
ssbehaviors
ssBlockade ssofsmuscarinic sscholinergic ssreceptors
▪ Blocks ssdopamine ss2 ssreceptors ssin ssthe
ssnigrostriatal spathway, ssimproving sstics ssand
▪ Hypotension, sstachycardia, sshypertension ss–
ssBlockingsof ssalpha ss1 ssadrenergic ssreceptors
ssother sssymptoms ssin
Tourette’s sssyndrome ▪ Weight ssgain ss- ssMechanism ssof ssweight ssgain
ssand ssany sspossible ssincreased ssincidence ssof
ssdiabetes ssor ssdyslipidemia sswith ssunconventional
ssantipsychotics ssis
currently ssunknown
Thioridazine Indication: Half ssLife ▪ Neuroleptic-induced ssdeficit sssyndrome ss– ssBlocking
ssof
, ▪ Schizophrenic sspatients sswho ssfail ssto ssrespond 21–24 sshours dopamine ss2 ssreceptors ssexcessively ssin ssthe
sstostreatment sswith ssother ssantipsychotic ssmesocortical ssand ssmesolimbic ssdopamine
ssdrugs sspathways, sespecially ssat sshigh ssdoses, ssit sscan
Target sssymptoms: Metabolized sscause ssworsening ssofsnegative ssand sscognitive
▪ Positive sssymptoms ssof sspsychosis ssin sspatients sswho ssPrimarily sssymptoms
ssfail sstosrespond ssto sstreatment sswith ssother ssby ssCYP450 ▪ Akathisia ss- ssAcute ssblockade ssof ssdopamine ss2
ssantipsychotics ssreceptorssin ssthe ssstriatum
ss- ss2D6
▪ Motor ssand ssautonomic sshyperactivity ssin sspatients sswho ▪ Priapism ss– ssBlocking ssof ssalpha ss1 ssadrenergic
ssfailsto ssrespond ssto sstreatment sswith ssother
ssreceptors
ssantipsychotics
▪ Drug-induced ssparkinsonism ss- ssAcute ssblockade
Potency: ssLow ssofsdopamine ss2 ssreceptors ssin ssthe ssstriatum
ssNeurotransmitter(s)
▪ Tardive ssdyskinesia ss- ssChronic ssblockade ssof
ssaffected: ssdopamines2 ssreceptors ssin ssthe ssstriatum
▪ Blocks ssdopamine ss2 ssreceptors, ssreducing ▪ Risk ssof sspotentially ssirreversible
sspositivessymptoms ssof sspsychosis
ssinvoluntary sdyskinetic ssmovements ssmay
ssincrease sswith sscumulative ssdose ssand
sstreatment ssduration
▪ Galactorrhea, ssamenorrhea ss- ssBlocking ssof
ssdopamines2 ssreceptors ssin ssthe sspituitary
▪ Pigmentary ssretinopathy ssat sshigh ssdoses ss–
ssmay ssbesdue ssto ssblockade ssof ssretinal ssD2/D4
ssreceptors
▪ Dizziness, sssedation ss- ssAntihistaminic
ssactions, sblocking ssof ssalpha ss1 ssadrenergic
ssreceptors
▪ Dry ssmouth, ssconstipation, ssblurred ssvision,
ssdecreasedssweating, ssparalytic ssileus ss– ssBlocking
ssof ssmuscarinic sscholinergic ssreceptors
▪ Sexual ssdysfunction ss- ssBlockade ssof ssdopamine
ssD2sreceptors ssin ssthe sstuberoinfundibular
sspathway
▪ Hypotension ss– ssBlocking ssof ssalpha ss1
ssadrenergicsreceptors
▪ Weight ssgain ss- ssAntihistaminic ssactions
▪ Mechanism ssof ssweight ssgain ssand ssany
sspossible ssincreased ssincidence ssof ssdiabetes ssor
ssdyslipidemia
with ssconventional ssantipsychotics ssis ssunknown
▪ Mechanism ssof sspotentially ssdangerous ssQTc
ssprolongation ssmay ssbe ssrelated ssto ssactions
ssat ssion
channels
, Thiothixene Indication: Half ssLife: ▪ Neuroleptic-induced ssdeficit sssyndrome ss- ssBlocking
▪ Schizophrenia ssInitial ssofsdopamine ss2 ssreceptors ssexcessively ssin ssthe
▪ Other sspsychotic ssdisorders sselimination: ssmesocortical ssand ssmesolimbic ssdopamine
▪ Bipolar ssdisorder ssapproximat sspathways, sespecially ssat sshigh ssdoses, sscan sscause
Target sssymptoms: el ssworsening ssof
y ss3.4 sshours negative ssand sscognitive sssymptoms
ss ss ss ss ss
Medications Table questions and detailed answers
ss ss ss ss ss ss ss
all question upgraded /newest version[grade a+]
ss ss ss ss ss ss
Antipsychotic Medications
ss
Kristin ssReddy ssNR ss546 ssSeptember
ss2022
Drug ssname Indication ss(Bold ss= ssFDA ssapproved) Half-life Notable ssside sseffects ss(associate ssto sspathway ssor ssNT)
Target sssymptoms: ssstate ssif sspositive ssor ssnegative s(T1/2),
sseffectsPotency ss(if ssnoted. ssreceptor ssoccupancy ssif metabolism
ssnoted) ssNeurotransmitter(s) ssaffected s(CYP ss450
enzyme)
Typical ssantipsychotics ss(conventional)
,Haloperidol Indication: Half s s Life ▪ Neuroleptic-induced ssdeficit sssyndrome ss– ssBlocking
▪ Manifestations ssof sspsychotic ssdisorders ssOral: ssofsdopamine sstwo ssreceptors ssexcessively ssin ssthe
ss(oral,simmediate-release ssinjection) ssApproximat mesocortical ssand ssmesolimbic ssdopamine
▪ Tics ssand ssvocal ssutterances ssin ssTourette’s sssyndrome elsy ss12-38 sspathways, sspecially ssat sshigh ssdoses, ssit sscan
ss(oral,simmediate-release ssinjection) hours sscause ssworsening ssof ssnegative ssand sscognitive
▪ Second-line sstreatment ssof sssevere ssbehavior sssymptoms
ssproblems ssinschildren ssof sscombative, ssexplosive Decanoate: ▪ Akathisia ss- ssAcute ssblockade ssof ssdopamine ss2
sshyperexcitability ss(oral) ssreceptorssin ssthe ssstriatum
ssapproximat
▪ Second-line ssshort-term sstreatment ssof elsy ss3 ssweeks ▪ Drug-induced ssparkinsonism ss- ssAcute ssblockade
ssofsdopamine ss2 ssreceptors ssin ssthe ssstriatum
sshyperactiveschildren ss(oral)
▪ Treatment ssof ssschizophrenic sspatients sswho ▪ Tardive ssdyskinesia, sstardive ssdystonia ss– ssChronic
ssandsacute ssblockade ssof ssdopamine ss2 ssreceptors
ssrequire ssprolonged ssparenteral ssantipsychotic Metabolized
ssin ssthe ssstriatum
sstherapy ss(depotsintramuscular ssdecanoate) sby ssCYP450
▪ Bipolar ssdisorder ▪ Risk ssof sspotentially ssirreversible
ss- ss2D6,
ssinvoluntary sdyskinetic ssmovements ssmay
▪ Behavioral ssdisturbances ssin ssdementias ss3A4,
ssincrease sswith sscumulative ssdose ssand
▪ Delirium ss(with 3A5
sstreatment ssduration
sslorazepam)sTarget sssymptoms:
▪ Positive sssymptoms ssof sspsychosis ▪ Galactorrhea, ssamenorrhea ss– ssBlocking ssof
ssdopamines2 ssreceptors ssin ssthe sspituitary sscan
▪ Violent ssor ssaggressive
sscause sselevations ssin
ssbehaviorsPotency: ssHigh
Neurotransmitter(s) ssaffected: prolactin
▪ Blocks ssdopamine ss2 ssreceptors, ssreducing ▪ Dizziness, sssedation ss– ssBlocking ssof ssalpha ss1
ssadrenergicsreceptors
sspositive ssymptoms ssof sspsychosis ssand sspossibly
sscombative, sexplosive, ssand sshyperactive
▪ Dry ssmouth, ssconstipation, ssurinary ssretention,
ssblurred ssvision, ssdecreased sssweating ss–
ssbehaviors
ssBlockade ssofsmuscarinic sscholinergic ssreceptors
▪ Blocks ssdopamine ss2 ssreceptors ssin ssthe
ssnigrostriatal spathway, ssimproving sstics ssand
▪ Hypotension, sstachycardia, sshypertension ss–
ssBlockingsof ssalpha ss1 ssadrenergic ssreceptors
ssother sssymptoms ssin
Tourette’s sssyndrome ▪ Weight ssgain ss- ssMechanism ssof ssweight ssgain
ssand ssany sspossible ssincreased ssincidence ssof
ssdiabetes ssor ssdyslipidemia sswith ssunconventional
ssantipsychotics ssis
currently ssunknown
Thioridazine Indication: Half ssLife ▪ Neuroleptic-induced ssdeficit sssyndrome ss– ssBlocking
ssof
, ▪ Schizophrenic sspatients sswho ssfail ssto ssrespond 21–24 sshours dopamine ss2 ssreceptors ssexcessively ssin ssthe
sstostreatment sswith ssother ssantipsychotic ssmesocortical ssand ssmesolimbic ssdopamine
ssdrugs sspathways, sespecially ssat sshigh ssdoses, ssit sscan
Target sssymptoms: Metabolized sscause ssworsening ssofsnegative ssand sscognitive
▪ Positive sssymptoms ssof sspsychosis ssin sspatients sswho ssPrimarily sssymptoms
ssfail sstosrespond ssto sstreatment sswith ssother ssby ssCYP450 ▪ Akathisia ss- ssAcute ssblockade ssof ssdopamine ss2
ssantipsychotics ssreceptorssin ssthe ssstriatum
ss- ss2D6
▪ Motor ssand ssautonomic sshyperactivity ssin sspatients sswho ▪ Priapism ss– ssBlocking ssof ssalpha ss1 ssadrenergic
ssfailsto ssrespond ssto sstreatment sswith ssother
ssreceptors
ssantipsychotics
▪ Drug-induced ssparkinsonism ss- ssAcute ssblockade
Potency: ssLow ssofsdopamine ss2 ssreceptors ssin ssthe ssstriatum
ssNeurotransmitter(s)
▪ Tardive ssdyskinesia ss- ssChronic ssblockade ssof
ssaffected: ssdopamines2 ssreceptors ssin ssthe ssstriatum
▪ Blocks ssdopamine ss2 ssreceptors, ssreducing ▪ Risk ssof sspotentially ssirreversible
sspositivessymptoms ssof sspsychosis
ssinvoluntary sdyskinetic ssmovements ssmay
ssincrease sswith sscumulative ssdose ssand
sstreatment ssduration
▪ Galactorrhea, ssamenorrhea ss- ssBlocking ssof
ssdopamines2 ssreceptors ssin ssthe sspituitary
▪ Pigmentary ssretinopathy ssat sshigh ssdoses ss–
ssmay ssbesdue ssto ssblockade ssof ssretinal ssD2/D4
ssreceptors
▪ Dizziness, sssedation ss- ssAntihistaminic
ssactions, sblocking ssof ssalpha ss1 ssadrenergic
ssreceptors
▪ Dry ssmouth, ssconstipation, ssblurred ssvision,
ssdecreasedssweating, ssparalytic ssileus ss– ssBlocking
ssof ssmuscarinic sscholinergic ssreceptors
▪ Sexual ssdysfunction ss- ssBlockade ssof ssdopamine
ssD2sreceptors ssin ssthe sstuberoinfundibular
sspathway
▪ Hypotension ss– ssBlocking ssof ssalpha ss1
ssadrenergicsreceptors
▪ Weight ssgain ss- ssAntihistaminic ssactions
▪ Mechanism ssof ssweight ssgain ssand ssany
sspossible ssincreased ssincidence ssof ssdiabetes ssor
ssdyslipidemia
with ssconventional ssantipsychotics ssis ssunknown
▪ Mechanism ssof sspotentially ssdangerous ssQTc
ssprolongation ssmay ssbe ssrelated ssto ssactions
ssat ssion
channels
, Thiothixene Indication: Half ssLife: ▪ Neuroleptic-induced ssdeficit sssyndrome ss- ssBlocking
▪ Schizophrenia ssInitial ssofsdopamine ss2 ssreceptors ssexcessively ssin ssthe
▪ Other sspsychotic ssdisorders sselimination: ssmesocortical ssand ssmesolimbic ssdopamine
▪ Bipolar ssdisorder ssapproximat sspathways, sespecially ssat sshigh ssdoses, sscan sscause
Target sssymptoms: el ssworsening ssof
y ss3.4 sshours negative ssand sscognitive sssymptoms
